Prostate Cancer Metastatic Hormone-Sensitive (mHSPC)
Reviewed by Oncology Team, VICI Healthcare | Last updated: 2026-04
What Metastatic Hormone-Sensitive (mHSPC) Means
M1 (bone or visceral metastases) at diagnosis, no prior hormone therapy
Treatment Approach for Metastatic Hormone-Sensitive (mHSPC)
Upfront ADT + docetaxel (STAMPEDE/CHAARTED trials showed docetaxel improves survival by 15–20 months). Alternatively, ADT – novel hormonal agent (abiraterone/enzalutamide). PSMA PET guides intensity.
Survival Rates and Prognosis
The 5-year survival rate for prostate cancer at Metastatic Hormone-Sensitive (mHSPC) is approximately 40%–60% (10-yr: 10%–25%). Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Very Low Risk | 99%+ (10-yr: 98%+) | Active surveillance preferred. Annual PSA, DRE, repeat biopsy in 1–2… |
| Low Risk | 98%+ (10-yr: 95%) | Active surveillance or definitive therapy (RARP or radiation). Discuss 10-year… |
| Intermediate Risk | 95% (10-yr: 88%–92%) | Definitive therapy: RARP with or without pelvic lymph node dissection, or EBRT… |
| High Risk | 88%–93% (10-yr: 75%–85%) | Definitive therapy + ADT. EBRT – 24–36 months ADT preferred if fit…. |
| Very High Risk | 70%–85% (10-yr: 55%–75%) | Aggressive systemic therapy. EBRT – 36+ months ADT with or without… |
| Metastatic Castration-Resistant (mCRPC) | 15%–30% (10-yr: <10%) | Sequence of hormone therapies (abiraterone, enzalutamide, apalutamide) or… |
Prostate Cancer Treatment in Top Cities
Prostate Cancer in Gurgaon
Prostate Cancer in Noida
Prostate Cancer in Mumbai
Prostate Cancer in Bangalore
Prostate Cancer in Hyderabad
Prostate Cancer in Chennai
Prostate Cancer in Kolkata
Diagnosed with Metastatic Hormone-Sensitive (mHSPC) Prostate Cancer?
Our specialists can review your reports and create a personalised treatment plan.